

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 73265

Title: Endothelial cells and blood vessels are major targets for COVID-19-induced tissue

injury and spreading to various organs

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06006212

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2021-11-15

Reviewer chosen by: Lian-Sheng Ma

Reviewer accepted review: 2021-11-18 06:25

Reviewer performed review: 2021-11-19 01:25

Review time: 18 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thank you very much for letting me contribute to this editorial article. Overall, the article is well organized and concise. Understanding and preventing extrapulmonary manifestation, including VTE, plays a critical role in improving outcomes of COVID-19. The present article stresses the importance of endothelial standpoint in COVID-19 development. Pathophysiological investigation and clinical trials are both essential to advance the knowledge of today. My concerns about this article are that the pathophysiological benefits of the two novel drugs, Molnupiravir and Paxlovid, were unclear. It is remarkable that we can keep the disease progress at bay by oral drugs. However, the endothelial effects of Molnupiravir were a bit vague. In addition, the results of Paxlovid study from Science were a little misleading because the main experiment was in vivo and did not demonstrate substantial efficacy in humankind. Considering the context of endothelial contribution to COVID-19 severity, I believe that the relationship between the two drugs and endothelial cells should be more clarified and emphasized.